Kyle Mikson
Stock Analyst at Canaccord Genuity
(2.12)
# 3,037
Out of 5,182 analysts
124
Total ratings
38.04%
Success rate
-2.73%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XGN Exagen | Maintains: Buy | $10 → $8 | $2.74 | +191.97% | 7 | Apr 20, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $170 → $100 | $66.17 | +51.13% | 4 | Apr 20, 2026 | |
| VCYT Veracyte | Maintains: Hold | $43 → $40 | $33.85 | +18.17% | 3 | Apr 20, 2026 | |
| TXG 10x Genomics | Maintains: Buy | $22 → $32 | $22.28 | +43.63% | 11 | Apr 20, 2026 | |
| RGEN Repligen | Maintains: Hold | $165 → $145 | $118.29 | +22.58% | 5 | Apr 20, 2026 | |
| QTRX Quanterix | Maintains: Hold | $8 → $4 | $3.21 | +24.61% | 9 | Apr 20, 2026 | |
| CSTL Castle Biosciences | Maintains: Buy | $50 → $40 | $24.98 | +60.13% | 7 | Apr 20, 2026 | |
| CAI Caris Life Sciences | Maintains: Hold | $30 → $22 | $19.93 | +10.39% | 3 | Mar 13, 2026 | |
| QSI Quantum-Si incorporated | Maintains: Hold | $1.5 → $1 | $0.90 | +11.07% | 7 | Mar 5, 2026 | |
| GH Guardant Health | Maintains: Buy | $125 → $135 | $88.50 | +52.54% | 11 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105 → $80 | $55.02 | +45.40% | 6 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $10.13 | +97.53% | 6 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $130 → $150 | $128.52 | +16.71% | 15 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $80 | $52.68 | +51.86% | 3 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $285 | $204.39 | +39.44% | 12 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.59 | +88.68% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.06 | +183.02% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.14 | +1,368.43% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,476 | $8.40 | +17,471.43% | 1 | Mar 30, 2021 |
Exagen
Apr 20, 2026
Maintains: Buy
Price Target: $10 → $8
Current: $2.74
Upside: +191.97%
GeneDx Holdings
Apr 20, 2026
Maintains: Buy
Price Target: $170 → $100
Current: $66.17
Upside: +51.13%
Veracyte
Apr 20, 2026
Maintains: Hold
Price Target: $43 → $40
Current: $33.85
Upside: +18.17%
10x Genomics
Apr 20, 2026
Maintains: Buy
Price Target: $22 → $32
Current: $22.28
Upside: +43.63%
Repligen
Apr 20, 2026
Maintains: Hold
Price Target: $165 → $145
Current: $118.29
Upside: +22.58%
Quanterix
Apr 20, 2026
Maintains: Hold
Price Target: $8 → $4
Current: $3.21
Upside: +24.61%
Castle Biosciences
Apr 20, 2026
Maintains: Buy
Price Target: $50 → $40
Current: $24.98
Upside: +60.13%
Caris Life Sciences
Mar 13, 2026
Maintains: Hold
Price Target: $30 → $22
Current: $19.93
Upside: +10.39%
Quantum-Si incorporated
Mar 5, 2026
Maintains: Hold
Price Target: $1.5 → $1
Current: $0.90
Upside: +11.07%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $125 → $135
Current: $88.50
Upside: +52.54%
Feb 20, 2026
Maintains: Buy
Price Target: $105 → $80
Current: $55.02
Upside: +45.40%
Feb 17, 2026
Maintains: Buy
Price Target: $20
Current: $10.13
Upside: +97.53%
Jan 26, 2026
Maintains: Hold
Price Target: $130 → $150
Current: $128.52
Upside: +16.71%
Dec 22, 2025
Maintains: Buy
Price Target: $95 → $80
Current: $52.68
Upside: +51.86%
Dec 22, 2025
Maintains: Buy
Price Target: $250 → $285
Current: $204.39
Upside: +39.44%
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.59
Upside: +88.68%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $1.06
Upside: +183.02%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.14
Upside: +1,368.43%
Mar 30, 2021
Initiates: Overweight
Price Target: $1,476
Current: $8.40
Upside: +17,471.43%